Etanercept for the treatment of rheumatoid arthritis

Immunotherapy
Sizheng ZhaoRobert J Moots

Abstract

Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease. Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, function, quality of life and mortality for these patients. It is structurally distinct from other TNF inhibitors and thus has desirable profiles for immunogenicity, drug survival and infection rate. With the increasing number of etanercept biosimilars, there will likely be a resurgence of their prescription. This article reviews the pharmacology, efficacy and safety of the etanercept reference product, and its biosimilars, in the context of RA treatment.

References

Jan 1, 1978·Journal of Chronic Diseases·H A IsomäkiU Joutsenlahti
May 1, 1984·British Journal of Rheumatology·P PriorC F Hawkins
May 12, 1994·The New England Journal of Medicine·J M Cash, J H Klippel
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
May 11, 2000·Seminars in Arthritis and Rheumatism·K M PugnerK Hieke
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Mar 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maria L OllerosIrene Garcia
Jun 14, 2003·Gastroenterology·Jan M H Van den BrandeSander J H van Deventer
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Mar 6, 2004·Lancet·Lars KlareskogUNKNOWN TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators
May 26, 2004·PharmacoEconomics·Tore K Kvien
Nov 25, 2004·Rheumatology·S MpofuR J Moots
Jan 11, 2005·Arthritis and Rheumatism·Désirée van der HeijdeSaeed Fatenejad
Apr 27, 2005·Seminars in Arthritis and Rheumatism·Paul J Anderson
Dec 13, 2006·Annals of the Rheumatic Diseases·Lennart T H JacobssonPierre Geborek
May 25, 2007·Drugs·Sohita DhillonLesley J Scott
Apr 17, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jay R McDonaldSeth A Eisen
Nov 4, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jasvinder A SinghPeter Tugwell
Sep 28, 2010·Lancet·David L ScottTom W J Huizinga
Feb 10, 2012·Clinical Pharmacology and Therapeutics·Mark McCamish, Gillian Woollett
Oct 12, 2012·Arthritis and Rheumatism·Kevin HaynesUNKNOWN SABER Collaboration

❮ Previous
Next ❯

Citations

Aug 28, 2020·Scandinavian Journal of Immunology·Bergithe E Oftedal, Anette S B Wolff
Feb 20, 2020·Science Signaling·Simone JensenOle Haagen Nielsen
Aug 17, 2019·Cells·Eliot Osher, Valentine M Macaulay
Apr 24, 2020·Molecular Medicine Reports·Yifan LvXiangyu Wang
Nov 5, 2020·Expert Opinion on Biological Therapy·Ciro RomanoGiovanna Cuomo
Jan 17, 2021·International Journal of Molecular Sciences·Piotr WójcikElżbieta Skrzydlewska
Nov 19, 2020·Annals of Medicine and Surgery·Ashraf O OweisDeeb Jamil Zahran
Jul 13, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Naibo Feng, Fengjin Guo
Aug 13, 2021·Advanced Science·Siyu WeiYongshuai Jiang

❮ Previous
Next ❯

Methods Mentioned

BETA
protein folding

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Therapeutics and Clinical Risk Management
Boulos Haraoui, Vivian P Bykerk
Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
L C Fernández LisónJ Liso Rubio
© 2022 Meta ULC. All rights reserved